|Day Low/High||105.03 / 106.47|
|52 Wk Low/High||68.02 / 107.26|
Less data will make investors more susceptible to negative headlines.
Stephanie Link, director of research at TheStreet, says CVS and Express Scripts are the real winners in Express Scripts' PBM agreement with Walgreen, and is buying CVS on today's pull back.
Mark Thierer, CEO of Catamaran, discusses the company's new name and branding and explains why Obamacare will benefit the PBM industry.
Today's market leaders indicate that funds want to put cash to work but they don't trust this market.
Stephanie Link, director of research at TheStreet, likes CVS for more than the market share they are gaining from Walgreen.
Brian Sozzi of Decoding Wall St. likes CVS over Walgreen's, even though some see it as a value stock.
Jill Malandrino and Scott Redler, chief strategic officer at T3Live.com, revealhow to trade stocks ahead of earnings season: retail, banks, tech.
J.C. Penney and Walgreen seem to have lost their way, to the benefit of their competitors.
The selloff in the drugstore chain's shares has made it a great buy for patient investors.
CVS Caremark and Beam Inc. offer investors a greater probability of advance if market woes continue.
In this episode of Buy This, Sell That!, David Perkins, portfolio manager for the Weitz Value Fund, names his favorite stocks including Flir Systems and CVS Caremark.
Consumer staples stocks have been running high, but these names still offer upside.
Global stocks were also trading to the plus side as Monday's NYSE gains set the pace for international indices.
Mild winter weather has affected many companies' sales and may be distorting the market view.
Valid reasons exist for ridding your value portfolio of a few stocks, plus you'll make room for new ones.